Compare BioNano Genomics Inc (BNGO) vs Workiva Inc (WK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Workiva Inc — how do they compare? BioNano Genomics Inc trades at $1.2 (market cap $13.66M), while Workiva Inc trades at $67.72 (market cap $3.76B). The key difference: Workiva Inc is far larger — about 275.3× BioNano Genomics Inc's market cap, and Workiva Inc is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | WK | |
|---|---|---|
Market Cap | $13.66M | $3.76B |
Sector | Health | Technology |
52-Week High | $4.92 | $93.31 |
52-Week Low | $1.06 | $44.31 |
Enterprise Value | $16.26M | $3.73B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.19, up 2.59% today, with bullish technical signals from moving averages. The company shows improving financials with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable. Recent earnings have consistently beaten expectations, and analyst sentiment is positive with 57% buy ratings. Key developments include debt retirement and scientific publications highlighting optical genome mapping adoption.
The outlook is cautiously optimistic given improving fundamentals and positive analyst coverage, but significant risks remain due to persistent losses and negative cash flow. Investment opportunity lies in the company's technology adoption growth, while primary risks include profitability challenges and competitive pressures in the genomics space.
Workiva (WK) trades at $67.62, up 0.45% with strong technical momentum and bullish analyst sentiment. The stock shows robust earnings performance with three consecutive quarterly beats and revenue growth accelerating to 19% in Q2 2026. Technical indicators signal bullish momentum despite overbought RSI conditions, while fundamentals reflect improving profitability with net income margin turning positive to 4.87% in 2026.
Outlook remains positive with 89% analyst buy ratings and $69 consensus target offering 2% upside. Key opportunities include AI product expansion and sustained subscription growth, while risks involve high valuation multiples (P/E 82.2) and competitive pressures in regulatory software. The stock's proximity to 52-week highs suggests momentum but warrants caution on pullbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
